The DEA's 7-OH Notice: What Retailers Need to Know (2026)

If you sell 7-hydroxymitragynine (7-OH) products at retail or move them through distribution, the federal landscape shifted in the first week of July 2026. This is a compliance and logistics briefing for business owners — what was filed, when it matters, which SKUs it captures, and the concrete steps a compliant retailer should take this week. It is not legal advice; consult counsel for your specific situation.

What did the DEA actually file?

On July 1, 2026, the DEA filed two Notices of Intent to temporarily place four substances into Schedule I of the Controlled Substances Act: concentrated 7-OH (7-hydroxymitragynine) and three analogues — mitragynine pseudoindoxyl, MGM-15, and MGM-16.

The notices publish in the Federal Register on July 6, 2026, under dockets DEA-1570 (7-OH, 91 FR 40917) and DEA-1644 (the three analogues, 91 FR 40909). Separately, the Department of Health and Human Services opened a Request for Information (HHS-OASH-2026-0232, 91 FR 41049) accepting public comments through July 31, 2026. A Notice of Intent is a filing that starts the clock — it is not yet an active ban.

When does the ban take effect?

The temporary scheduling order cannot take effect until at least 30 days after the July 6, 2026 publication — that is, on or after roughly August 5, 2026. The mechanism is the DEA's emergency scheduling authority under 21 U.S.C. 811(h).

A few practical points for planning:

• The initial temporary term is two years, extendable to three.
• Making the schedule permanent would require a separate rulemaking process, which has not started as of this writing.
• As of July 4, 2026, no lawsuit challenging the scheduling has been filed. Industry litigation could still come, but nothing has been filed to date.

Bottom line: retailers have a short window, but you should treat early August as the operative date and plan sell-through, returns, and restocking decisions around it.

What is the threshold, and which SKUs does it capture?

This is the most important paragraph for your inventory review. The proposed scheduling captures:

• Mitragyna speciosa plant material containing more than 0.050% 7-OH by dry weight, OR
• Any extract, concentrate, edible, or pressed article containing more than 0.050% 7-OH by weight OR more than 1.00 mg of 7-OH per article (per tablet, gummy, shot, etc.).

Natural kratom leaf is excluded. The notice is aimed at concentrated and semi-synthetic 7-OH — the pressed tablets, high-potency extracts, and edibles — not traditional whole-leaf kratom that sits below the threshold. In practice, most branded "7-OH tablet" and concentrate SKUs on the market today exceed 1.00 mg per article and would be captured. You cannot eyeball this: the per-article milligram figure and the percent-by-weight figure both come from lab testing, which is why COAs are non-negotiable (more below).

Is there a payment-processing risk before the ban even lands?

Yes — and it may hit sooner than the DEA order. Independent of federal scheduling, card-network and processor rules already restrict 7-OH transactions. Mastercard's BRAM (Business Risk Assessment and Mitigation) program and comparable network rules treat these products as high-risk, and processors monitor merchant activity and can terminate accounts without waiting for a scheduling order to take effect.

For a retailer, that means a frozen merchant account, held funds, or a sudden inability to run cards can arrive with little warning. If 7-OH is a meaningful share of your revenue, talk to your processor now, understand your MCC classification, and have a contingency plan for payments before you have a compliance problem.

Doesn't state law matter too?

Very much so — and state law can be stricter and faster than the federal timeline. Several states have already restricted or banned 7-OH or kratom outright. As of July 1, 2026 this includes states with 7-OH-specific restrictions such as Florida, Ohio, and Mississippi, plus full kratom-ban states like Tennessee and Kansas. This list is not exhaustive and it changes frequently.

Verify your own state and any state you ship into before you sell. Federal scheduling sets a floor, not a ceiling — a product that is not yet federally scheduled can still be illegal in your jurisdiction today.

What should a compliant retailer do right now?

1. Verify state law. Confirm the current status of 7-OH in your state and every state you ship to. Re-check regularly — statutes and emergency rules are moving fast.
2. Audit your inventory against the threshold. Identify every SKU that exceeds 0.050% by weight or 1.00 mg 7-OH per article. Those are the products captured by the proposed federal order.
3. Model your sell-through window. Treat on-or-after August 5, 2026 as the operative federal date and plan purchasing, promotions, and returns accordingly.
4. Demand current COAs. Require a recent Certificate of Analysis from every supplier showing 7-OH content by weight and per article. Without lab data you cannot know which side of the threshold a product sits on — or defend your decisions later.
5. Lock down payments. Confirm your processor's stance on 7-OH and secure a backup before an account action interrupts sales.
6. Document everything. Keep records of your state-law checks, COAs, and supplier communications. Good documentation is your best protection in a shifting regulatory environment.

Frequently asked questions

Can retailers still sell 7-OH right now?

As of July 4, 2026, the federal temporary scheduling order has not taken effect — it cannot before roughly August 5, 2026. However, several states have already restricted or banned 7-OH, and payment processors may act independently. Whether you can legally sell depends on your specific state and your processor's rules, so verify both before selling.

Does this ban apply to regular kratom leaf?

No. Natural kratom leaf is excluded. The proposed order targets material and articles that exceed 0.050% 7-OH by weight or 1.00 mg per article — that is, concentrated, extracted, and pressed 7-OH products, not traditional whole-leaf kratom below the threshold.

How long would the temporary ban last?

The temporary Schedule I placement has an initial term of two years, extendable to three. Permanent scheduling would require a separate rulemaking process that has not yet begun.

What is a distributor's exposure heading into 2026?

A 7-OH distributor in 2026 faces three overlapping risks: the federal temporary schedule taking effect on or after August 5, state-level bans that are already active, and payment-processor termination that can happen at any time. Manage inventory, contracts, and payments against all three, not just the federal date.

Where can I read the primary sources?

The Federal Register notices publish July 6, 2026 under dockets DEA-1570 (91 FR 40917) and DEA-1644 (91 FR 40909), with the HHS Request for Information at HHS-OASH-2026-0232 (91 FR 41049), open for comment through July 31, 2026.

---

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. For adults 21 and older, where legal.

This article is for general business information only and is not legal advice. Consult qualified counsel and verify current federal and state law before making compliance decisions.